Clinical Insights: December 13, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Casgevy™ (exagamglogene autotemcel) – New Drug Approval – December 8, 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced that the U.S. Food and Drug Administration…
Our Final Podcast Episode of 2023!
RPh Innovation’s role in providing professional support services, including price file verifications and eligibility management, underscores the crucial need for strategic partnerships to optimize savings potential in the 340B landscape. In our latest 340B Insider Podcast episode, “Navigating the Complexities of 340B” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Robert Johnson RPh, founder of…
Clinical Insights: December 6, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 05, 2023 Fluorescein Sodium Injection (Resolved) December 01, 2023 Azacitidine Injection (Currently in Shortage) Hydroxypropyl Cellulose…
Clinical Insights: November 29, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ogsiveo™ (nirogacestat) Tablets – New Drug Approval – November 27, 2023 – The U.S. Food and Drug Administration approved Ogsiveo™ (nirogacestat) tablets for adult patients with progressing desmoid tumors who…
Clinical Insights: November 22, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Truqap™ (capivasertib) Tablets – New Drug Approval – November 16, 2023 – AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) has been approved in the US for the treatment of…
Clinical Insights: November 15, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ixchiq® (chikungunya vaccine, live) Injection – New Vaccine Approval – November 9, 2023 – The U.S. Food and Drug Administration approved Ixchiq®, the first chikungunya vaccine. Ixchiq® is approved for…
Clinical Insights: November 8, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Voquezna® (vonoprazan) Tablets – New Drug Approval – November 1, 2023 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal…
Clinical Insights: November 1, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Loqtorzi™ (toripalimab-tpzi) Injection – New Drug Approval – October 27, 2023 – The Food and Drug Administration approved toripalimab-tpzi (Loqtorzi™, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line…
Clinical Insights: October 25, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Penbraya (meningococcal groups A, B, C, W, and Y vaccine) Injection – New Vaccine Approval – October 20, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and…
Clinical Insights: October 18, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Velsipity™ (etrasimod) Tablets – New Drug Approval – October 12, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod),…
Clinical Insights: October 11, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Cosentyx® (secukinumab) Injection – New Label Expansion – October 6, 2023 – Novartis, a global leader in immuno-dermatology and rheumatology, announced that the…
RxStrategies to attend the FOM/IT Conference
The RxStrategies team is thrilled to be attending the upcoming 2023 NACHC Financial, Operations Management / Information Technology (FOM/IT) Conference and Expo in Las Vegas, October 24-25. We will be joining over 700 health center senior leaders, managers, CEOs, CFOs, COOs, CIOs and finance, operations and IT staff in from across the country, and…